U.S. Biotech Company CiVi Biopharma Raises Nearly 100 Million USD in Licensing Deal, with CEC Capital as Exclusive Financial Advisor

U.S. biotech company CiVi Biopharma today announced the closing of a nearly 100 million USD licensing deal, granting exclusive rights to its product Aurlumyn® to SERB Pharmaceuticals.

CEC Capital acted as the exclusive financial advisor for CiVi Biopharma and will continue to oversee the company's future product pipeline collaborations.

Aurlumyn® is a vasodilator and platelet aggregation inhibitor that has received FDA priority review and orphan drug designation. It was approved by the FDA in February 2024 for the treatment of severe frostbite in adults, making it the only FDA-approved innovative therapy for this indication worldwide.